GENERATED BY HUMANIZILY AGENT Severe Insulin Resistance Syndromes: Clinical Spectrum, Pathophysiology, and Management Strategies August 20, 2026Human score 64 CONTENTS  Introduction to Severe Insulin Resistance Syndromes (SIRS)  Characteristics and Pathophysiology of SIRS  Specific Types of Severe Insulin Resistance Syndromes  Management and Therapeutic Strategies for SIRS  Open questions 20/08/2026 23:17Severe Insulin Resistance Syndromes: Clinical Spectrum, Pathophysiology, and Management Strategies about:blank1/11 Introduction to Severe Insulin Resistance Syndromes (SIRS) Insulin resistance is a common condition in which cells don’t respond well enough to insulin, and it sits behind illnesses like type 2 diabetes, metabolic syndrome, hypertension, obesity, and polycystic ovary syndrome [1][2] . It can trigger a cascade of metabolic woes—hyperglycemia, hyperinsulinemia, dyslipidemia, hyperuricemia, endothelial dysfunction, raised inflammatory markers, and a prothrombotic state [1] . Small steps, big consequences. Severe insulin resistance syndromes (SIRS) form a heterogeneous, rare group defined by profound insulin resistance, marked metabolic abnormalities, and a spectrum of clinical clues and complications [1] . Prevalence isn’t pinned down precisely, but estimates suggest about 0.1–0.5% of diabetic patients might have SIRS [3] . A lot of it is hereditary or acquired, tied to defects in insulin action, cellular responsiveness, or adipose tissue function and development [1] . The fallout is serious: higher risk of death and serious complications across the board [1] . These syndromes arise from a mix of genetic and environmental factors. Because they’re diverse, treatments hit each type differently, depending on the specific insulin-resistance profile and the person presenting it [4] . Management aims to calm metabolic chaos and pathophysiology through lifestyle changes plus medications when appropriate, though no universal SIRS guideline exists, and there aren’t drugs specifically approved for insulin resistance itself [4] . In practice, that means nutrition and activity come first, with targeted therapies added as needed. 20/08/2026 23:17Severe Insulin Resistance Syndromes: Clinical Spectrum, Pathophysiology, and Management Strategies about:blank2/11 Characteristics and Pathophysiology of SIRS Severe insulin resistance syndromes (SIRS) are a rare, heterogeneous set of disorders. They come with deep insulin resistance, major metabolic disruption, and a wide array of clinical features. The causes can be inherited or acquired, stemming from problems with insulin binding, signaling, or adipose tissue development. Insulin resistance means skeletal muscle, fat, and the liver don’t respond well to insulin, even when insulin is normal or high in the blood. This faulty signaling sparks compensatory responses that drive hyperinsulinemia, build up fatty substrates, and fuel lipotoxicity, oxidative stress, inflammation, cell death, and tissue fibrosis. Genetic roots are a major driver, especially in monogenic forms; for example, most hereditary severe insulin-resistance syndromes (H-SIRS) link to mutations in the INSR gene. Specific INSR mutations can disrupt insulin binding or transmembrane signaling, throwing off downstream pathways. Other genes involved in H-SIRS include RECQL2, RECQL3, ALMS1, PCNT, ZMPSTE24, PIK3R1, and POLD1. Beyond genetics, lifestyle factors like physical inactivity, circadian misalignment, and high-calorie diets can topple metabolic balance, setting the stage for insulin resistance. Internal environmental abnormalities— chronic inflammation, hypoxia, and immune dysregulation—also contribute to the problem. 20/08/2026 23:17Severe Insulin Resistance Syndromes: Clinical Spectrum, Pathophysiology, and Management Strategies about:blank3/11 Specific Types of Severe Insulin Resistance Syndromes Severe insulin resistance syndromes (SIRS) cover a small, varied set of rare diseases marked by profound insulin resistance, messy metabolic clues, and a spectrum of clinical signs. These conditions can be inherited or come on later in life, arising from problems with how insulin works, how cells respond to it, or how fat tissue develops and functions [5][6] . They’re usually grouped by what goes wrong—receptor defects, signaling glitches, or lipodystrophies [5] . Because these syndromes are uncommon and often look like more familiar conditions such as type 2 diabetes or PCOS, misdiagnosis or late diagnosis happens, which raises the risk of serious complications and death [5][7] . Type A insulin resistance syndrome Type A insulin resistance syndrome (TAIRS) is a rare inherited condition caused by mutations in the insulin receptor gene (INSR). It can pass down in autosomal dominant or recessive fashion [7] . Key clues are severe insulin resistance, high androgens, hirsutism, and acanthosis nigricans (AN) [7] . In women, TAIRS often shows PCOS-like changes in the ovaries, making diagnosis tricky because the symptoms overlap so much with PCOS [7] . This overlap leads to frequent misdiagnosis, especially in teenage girls who may have very high insulin levels and hyperandrogenism even if they aren’t overweight [7] . Judging TAIRS apart from type 2 diabetes by hyperinsulinemia alone is hard. Yet new data point to the CPR/IRI molar ratio as a strong discriminator because INSR problems curb insulin clearance [8] . In a retrospective look, TAIRS patients had higher insulin and lower CPR/IRI ratios than those with type 2 diabetes [8] . The CPR/IRI ratio showed high sensitivity (100%) and specificity (95–99%) at baseline and during an oral glucose tolerance test, regardless of body mass index or how severe the hyperinsulinemia is [8] . This ratio outperforms IRI alone and can aid early, accurate diagnosis [8] . Many pathogenic INSR variants have been found in TAIRS, including missense, nonsense, insertions, deletions, and complex rearrangements [9] . New variants keep expanding the catalog; for example, a de novo heterozygous variant (p.Asp1110His) was found in a 12- year-old girl with TAIRS, while other cases involve mutations like c.2663A>G (p.Tyr888Cys) and c.38_61del (p.Pro13_Ala20del) [9][7] . Mutations in areas such as the junction between the α and β subunits or within the α subunit can mess with signaling or insulin binding, respectively [9] . Type B insulin resistance syndrome Type B insulin resistance (TBIR) is a rare autoimmune condition, not a genetic one. It crops up when IgG autoantibodies attack the insulin receptor [10] . Those antibodies act like 20/08/2026 23:17Severe Insulin Resistance Syndromes: Clinical Spectrum, Pathophysiology, and Management Strategies about:blank4/11 partial adapters, giving a two-step glycemic ride: severe insulin resistance with hyperglycemia when antibody levels are high, then hypoglycemia when they fall [10] . TBIR mainly hits middle‑aged women with preexisting autoimmune diseases but isn’t limited to them and can involve younger people of different backgrounds [10] . Clinically, TBIR brings severe insulin resistance and high blood sugar, but hypoglycemia can also occur, along with skin changes like acanthosis nigricans around the eyes, lips, and mucous‑rich areas [10] . Labs often show high adiponectin and triglycerides that aren’t consistently elevated, despite the insulin resistance [10] . Early recognition matters because immunosuppressive therapy can reverse the turmoil and put the disease into remission [10] . Looking ahead, combination immunosuppression has yielded about an 86% remission rate with no deaths in some trials, while systematic reviews cite around 70% remission and a 7% relapse rate [10] . Donohue syndrome and Rabson‑Mendenhall syndrome Donohue syndrome (DS) and Rabson‑Mendenhall syndrome (RMS) sit at the severe end of insulin receptor dysfunction. Both stem from biallelic loss‑of‑function INSR mutations. RMS is autosomal recessive and shows extreme insulin resistance, slow growth, dental anomalies (like missing teeth or misalignment), hirsutism, and AN [11] . Patients often have high insulin, high glucose, and a body weight that's off‑beat for their stage of illness, swinging between underweight and obesity as the disease evolves [11] . Many cases emerge before age 23, with a typical onset around age 9 [11] . The outlook is grim. DS usually doesn’t spare infants, and RMS has a markedly shortened life span compared with type 2 diabetes. Treatments like recombinant human IGF‑1 (rhIGF‑1) can help a bit with blood sugar, fasting tolerance, and growth early on, but they don’t stop the disease from spiraling toward diabetes. Growth potential often remains below normal, and some patients can’t tolerate rhIGF‑1, sometimes dying in infancy [12][13] . New problems linked to severe insulin receptor problems include cataracts, liver hemangiomas, and poor hepatic protein production [12] . Guidelines from bodies like BSPED allow rhIGF‑1 for SIR secondary to insulin receptoropathy when standard therapies fail, but rhIGF‑1 isn’t licensed for this use because of risks such as low blood sugar, enlarged lymphoid tissue, and intracranial pressure issues [14] . The genetic‑level data needed to guide targeted treatments is still weak, thanks to the rarity of these conditions and the lack of large, controlled trials [15] . Lipodystrophy and other genetic forms Lipodystrophy forms involve faulty fat tissue development or function, driving severe [5] 20/08/2026 23:17Severe Insulin Resistance Syndromes: Clinical Spectrum, Pathophysiology, and Management Strategies about:blank5/11 insulin resistance plus metabolic problems such as diabetes and lipid trouble [5] . Metreleptin, a recombinant leptin, has shown improvements in HbA1c, triglycerides, and body weight across various lipodystrophy genotypes [15] . Thiazolidinediones (TZDs), especially pioglitazone, help by boosting insulin sensitivity and raising adiponectin, though they must be used with care in generalized lipodystrophy [5] . Other genetic forms of SIRS include glucokinase‑MODY (GCK‑MODY), which can masquerade as severe insulin resistance when obesity and a family history of type 2 diabetes stack the deck [16] . Transient glutamic acid decarboxylase antibody (GADA) positivity may arise from metabolic stress rather than autoimmune pathogenesis, muddying the differential [16] . Hereditary severe insulin-resistance syndrome (H-SIRS) linked to INSR mutations presents with hyperinsulinemia, fasting hypoglycemia, postprandial hyperglycemia, fatty liver, and hyperandrogenism [9] . Genetic testing is vital for determining the etiology of insulin resistance across these diverse presentations [9] . Diagnosis hinges on testing. 20/08/2026 23:17Severe Insulin Resistance Syndromes: Clinical Spectrum, Pathophysiology, and Management Strategies about:blank6/11 Management and Therapeutic Strategies for SIRS Treating Severe Insulin Resistance Syndromes (SIRS) demands a multi-pronged strategy, from early recognition to targeted therapies like recombinant human insulin-like growth factor I (rhIGF-1). Clinicians need to pinpoint the underlying causes early so treatment can be tailored and outcomes improved. In extreme insulin resistance driven by insulin receptoropathies such as Donohue syndrome and Rabson‑Mendenhall syndrome, standard regimens—huge insulin doses and insulin sensitizers—often fall flat, leaving patients with bleak trajectories. rhIGF‑1 has emerged as a possible option because insulin and IGF‑1 share tyrosine kinase receptors. This overlap lets rhIGF‑1 engage alternative pathways, albeit with lower affinity, and can lift metabolic control by boosting glucose uptake in peripheral tissues and suppressing hepatic gluconeogenesis. Yet the clinical picture is mixed. Long‑term data show modest glycemic gains and improved fasting tolerance with frequent dosing (up to three times daily), but progression to diabetes isn’t halted. Growth outcomes are modest at best; many patients end up shorter than peers despite some early growth spurts. Safety concerns color the verdict. Reported rhIGF‑1 adverse events include hypoglycemia, lymphoid tissue hyperplasia, intracranial hypertension, slipped capital femoral epiphysis, and facial coarsening. In severe cases, two infants with resistance to rhIGF‑1 either did not respond or could not tolerate the therapy and died. Because of these risks and the small, heterogeneous case series, rhIGF‑1 remains unlicensed for SIRS in many jurisdictions, though it is approved for Severe Primary IGF‑I Deficiency. Guidance from BSPED offers a practical framework for pediatric use. Dosing for SIR is higher than for SPIGFD, with a ceiling of 0.2 mg/kg per dose, given subcutaneously twice daily. Local supervision by clinicians skilled in complex diabetes, with support from higher‑level quaternary centers, is advised. Monitoring mirrors SPIGFD protocols, covering contraindications, initiation, maintenance, and discontinuation. Given the rarity of these conditions and the absence of controlled trials, clinical judgment remains essential for decision making. 20/08/2026 23:17Severe Insulin Resistance Syndromes: Clinical Spectrum, Pathophysiology, and Management Strategies about:blank7/11 Open questions Severe insulin resistance syndromes (SIRS) are a rare, heterogeneous set of disorders. They come with deep insulin resistance, major metabolic disruption, and a wide array of clinical features. The causes can be inherited or acquired, stemming from problems with insulin binding, signaling, or adipose tissue development. Insulin resistance means skeletal muscle, fat, and the liver don’t respond well to insulin, even when insulin is normal or high in the blood. This faulty signaling sparks compensatory responses that drive hyperinsulinemia, build up fatty substrates, and fuel lipotoxicity, oxidative stress, inflammation, cell death, and tissue fibrosis. Genetic roots are a major driver, especially in monogenic forms; for example, most hereditary severe insulin-resistance syndromes (H-SIRS) link to mutations in the INSR gene. Specific INSR mutations can disrupt insulin binding or transmembrane signaling, throwing off downstream pathways. Other genes involved in H-SIRS include RECQL2, RECQL3, ALMS1, PCNT, ZMPSTE24, PIK3R1, and POLD1. Beyond genetics, lifestyle factors like physical inactivity, circadian misalignment, and high-calorie diets can topple metabolic balance, setting the stage for insulin resistance. Internal environmental abnormalities— chronic inflammation, hypoxia, and immune dysregulation—also contribute to the problem. References  ijms-26-05669.pdf — uploaded file — https://tbwxsi3ddbw4qifa.public.blob.vercel-storage.com/upload s/text/ijms-26-05669.pdf-jWgj6UgxvXZsjETwJLMz4w1u1XXRo5.txt  Severe Insulin Resistance Syndromes: Clinical Spectrum ... — mdpi.com — https://www.mdpi.com/14 22-0067/26/12/5669  Severe Insulin Resistance Syndromes: Clinical Spectrum and Management — pdfs.semanticscholar. org — https://pdfs.semanticscholar.org/d984/a7071015200e27979cdf8d52c14b99e9d71c.pdf  Severe Insulin Resistance Syndromes: Clinical Spectrum and Management. - Abstract - Europe PM C — europepmc.org — https://europepmc.org/article/MED/40565151  Severe Insulin Resistance Syndromes: Clinical Spectrum ... — pubmed.ncbi.nlm.nih.gov — https://pu bmed.ncbi.nlm.nih.gov/40565151  JCI - Severe insulin resistance syndromes — jci.org — https://www.jci.org/articles/view/142245  Severe insulin resistance syndromes — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/P MC7880309  Severe Insulin Resistance: Diagnosis and Management — pubmed.ncbi.nlm.nih.gov — https://pubme d.ncbi.nlm.nih.gov/40968430  Insulin Resistance - StatPearls - NCBI Bookshelf — ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/b ooks/NBK507839 20/08/2026 23:17Severe Insulin Resistance Syndromes: Clinical Spectrum, Pathophysiology, and Management Strategies about:blank8/11  Genetic Syndromes of Severe Insulin Resistance - Oxford Academic — academic.oup.com — https:// academic.oup.com/edrv/article/32/4/498/2354745  Publication – Severe Insulin Resistance Syndromes: Clinical Spectrum and Management – Polish Pla tform of Medical Research — ppm.edu.pl — https://ppm.edu.pl/info/article/WUMf3c4bed12dfa4efc875c b8b9e319d12b  Metabolic crossroads in insulin resistance: exploring lipid ... — frontiersin.org — https://www.frontiers in.org/journals/immunology/articles/10.3389/fimmu.2025.1692742/full  Insulin Resistance at the Crossroads of Metabolic ... - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.nc bi.nlm.nih.gov/articles/PMC12730331  Severe Insulin Resistance Syndromes: Clinical Spectrum and ... — pmc.ncbi.nlm.nih.gov — https://p mc.ncbi.nlm.nih.gov/articles/PMC12192740  The crucial role and mechanism of insulin resistance in ... — frontiersin.org — https://www.frontiersin. org/journals/endocrinology/articles/10.3389/fendo.2023.1149239/full  Utility of the C-Peptide/Insulin Molar Ratio for Distinguishing Type A Insulin Resistance Syndrome F rom Type 2 Diabetes | Endocrine Society — endocrine.org — https://www.endocrine.org/journals/jcem/ cpr-iri-molar-ratio-for-type-a-irs-and-t2  Frontiers | Type B insulin resistance with glycemic extremes: a case report and literature review — f rontiersin.org — https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1852784/ full  Severe Insulin Resistance: Diagnosis and Management | Bentham Science Publishers — benthamdir ect.com — https://www.benthamdirect.com/content/journals/cdr/10.2174/01157339983900482509021138 45  Insulin resistance: mechanisms and therapeutic interventions — link.springer.com — https://link.spri nger.com/article/10.1186/s43556-026-00408-5  RF16 | PSUN335 Clinical Effects of Sodium Glucose Transporter Type 2 Inhibitors in Patients with S evere Insulin Resistance — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9625456  Frontiers | Case report: A case of Rabson–Mendenhall syndrome: long-term follow-up and therapeu tic management with empagliflozin — frontiersin.org — https://www.frontiersin.org/journals/genetics/ar ticles/10.3389/fgene.2024.1414451/full  Genotype-stratified treatment for monogenic insulin resistance: a systematic review | Communicati ons Medicine — nature.com — https://www.nature.com/articles/s43856-023-00368-9  TCOYD's Crystal Ball: Our Diabetes Predictions for 2026! — tcoyd.org — https://tcoyd.org/2025/12/di abetes-predictions-2026  Insulin Resistance Pipeline Insight 2025 — openpr.com — https://www.openpr.com/news/4179782/insu lin-resistance-pipeline-insight-2025-pipeline-drugs  Multivariate genome-wide analyses of insulin resistance unravel novel loci and therapeutic targets for cardiometabolic health | Nature Communications — nature.com — https://www.nature.com/article s/s41467-025-64985-9  Frontiers | Case Report: A novel likely pathogenic GCK variant in a young Chinese girl with severe in sulin resistance — frontiersin.org — https://www.frontiersin.org/journals/endocrinology/articles/10.3389/ fendo.2026.1826357/full 20/08/2026 23:17Severe Insulin Resistance Syndromes: Clinical Spectrum, Pathophysiology, and Management Strategies about:blank9/11  Hereditary Severe Insulin-resistance Syndrome and Acanthosis Nigricans Caused by Novel Mutatio ns in the INSR Gene - Journal of Clinical Research in Pediatric Endocrinology — jcrpe.org — https:// www.jcrpe.org/articles/hereditary-severe-insulin-resistance-syndrome-and-acanthosis-nigricans-caused- by-novel-mutations-in-the-lessemgreaterinsrlessemgreater-gene/doi/jcrpe.galenos.2024.2024-2-14  Hereditary Severe Insulin-resistance Syndrome and Acanthosis Nigricans Caused by Novel Mutatio ns in the INSR Gene - Journal of Clinical Research in Pediatric Endocrinology — jcrpe.org — https://j crpe.org/articles/hereditary-severe-insulin-resistance-syndrome-and-acanthosis-nigricans-caused-by-nov el-mutations-in-the-lessemgreaterinsrlessemgreater-gene/jcrpe.galenos.2024.2024-2-14  Identification of Interactive Genetic Loci Linked to Insulin Resistance in Metabolic Syndrome—An U pdate — mdpi.com — https://www.mdpi.com/1648-9144/61/1/83  Genome-Wide Discovery Reveals Adipose-Specific and Systemic ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/41959785  Multivariate genome-wide analyses of insulin resistance ... — pmc.ncbi.nlm.nih.gov — https://pmc.nc bi.nlm.nih.gov/articles/PMC12623863  Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center ex perience — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/41606799  Rabson-Mendenhall Syndrome: Analysis of the Clinical Characteristics and Gene Mutations in 42 P atients - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11216847  A multicenter, open-label, single-arm trial of the long-term safety of empagliflozin treatment for ref ractory diabetes mellitus with insulin resistance (EMPIRE-02) — pubmed.ncbi.nlm.nih.gov — https:// pubmed.ncbi.nlm.nih.gov/38702973  A Case Report: Treatment, follow-up, and literature review of type A insulin resistance syndrome ca used by a De Novo INSR c.3328G>C mutation — doi.org — https://doi.org/10.3389/fendo.2026.184094 2  Clinical spectrum of extreme insulin resistance syndromes ... — academic.oup.com — https://acade mic.oup.com/jcem/article/111/7/2049/8443987  Clinical spectrum of extreme insulin resistance syndromes treated ... — academic.oup.com — http s://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/clinem/dgag031/8443987  Achievements, prospects and challenges in precision care for monogenic insulin-deficient and insu lin-resistant diabetes | Diabetologia | Springer Nature Link — link.springer.com — https://link.springe r.com/article/10.1007/s00125-022-05720-7  BSPED Recommendations for Recombinant IGF-I Therapy in Children with Severe Insulin Resistanc e Syndromes — bsped.org.uk — https://www.bsped.org.uk/media/anyb3gi2/recom-igf-i-ther-in-child-se vere-in-resist-syn_dec25.pdf  INSR-Related Severe Insulin Resistance Syndrome - GeneReviews® - NCBI Bookshelf — ncbi.nlm.ni h.gov — https://www.ncbi.nlm.nih.gov/books/NBK476444  Clinical Guidelines for the Diagnosis and Management of Generalized and Partial Lipodystrophies: A Position Statement Endorsed by the Hellenic Endocrine Society - PubMed — pubmed.ncbi.nlm.ni h.gov — https://pubmed.ncbi.nlm.nih.gov/41713690  The American Diabetes Association Releases Standards of Care in ... — diabetes.org — https://diabe tes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2025  Review article Hereditary severe insulin resistance syndrome: Pathogenesis, pathophysiology, and clinical management — sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S23523 20/08/2026 23:17Severe Insulin Resistance Syndromes: Clinical Spectrum, Pathophysiology, and Management Strategies about:blank10/11 04222000915  hot issues, trends, future directions, and bibliometric analysis - PMC — pmc.ncbi.nlm.nih.gov — http s://pmc.ncbi.nlm.nih.gov/articles/PMC12465385 20/08/2026 23:17Severe Insulin Resistance Syndromes: Clinical Spectrum, Pathophysiology, and Management Strategies about:blank11/11